reason report
bottom line host ninth annual svb leerink global
healthcar confer start tomorrow februari
join manag compani prepar
global healthcar confer analyst compos question
tailor manag team meet manag
listen present next day think find
answer question help gain invest edg
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
make differ fibroblast growth factor fgf develop advantag glycopegyl
concern year behind leader market make difficult enrol later-stag studi
across patient see util real-world commerci set
date appear favor safety/toler profil compar fgf compound albeit limit sampl size
believ gi toxic observ fgf compound class effect believ abl avoid
describ data give confid may effect revers fibrosi
one competitor recent announc includ nash patient cirrhosi phase studi think
util cirrhot patient impact develop plan
think combin market point could use combin would attract
pair includ
see nash market would will commerci
think potenti indication-bas price nash shtg
top-line phase trial data nafld/nash patient
initi phase studi shtg patient
competitor phase data
short interest float
walk capit alloc strategi among intern dividend debt repay
expect oper margin combin compani next five year rough breakdown synergi
cog sg
see allergan deal versu month ago
big tail opportun us humira combin compani grow inevit year
talk skyrizi rinvoq opportun futur label expans
key readout watch pipelin molecul mid-to-l develop underappreci could move
needl newco
regard hematolog franchis maintain lead posit cll competit intensifi
confid ftc decis propos divestitur brazikumab astrazeneca given latest push back union
short interest float
appear competit advantag address larg
see potenti approv base
chronic wound dystroph epidermolysi bullosa deb patient
heparin sulfat biomark long-term neurocognit data
could talk unmet need deb abil eb-
thought critic approv
address
see competit postion compar
think valu proposit gene
novel gene therapi clinic
therapi expect durat year cost offset play
advantag vector iv administr therapi
signific role clinic benefit alon bring lot valu
patient
healthcar system
clinic pipelin lysosom storag diseas crowd
signific cognit behavior benefit patient
see clinic trial enrol challeng
treat compar natur histori sanfilippo
syndrom type mp iiia would expect greater degre
clinic benefit patient treat earlier cours diseas
complet enrol phase trial recess dystroph
phase data readout trial rdeb
short interest float
analyst daniel antalffi medic suppli devic
earli day public data
reimburs cut line signific cut propos
jama impact treat refer physician vs
last year could absorb price cut
weve alreadi see counter-detail
 intern
come aha patient select seem like key take-away
might chang impella much
improv util trend februari
outcom come patient select vs oper
vs januari m/m weak decemb
ramp spend counter-detail effort
look ahead right way think
random control trial potenti neg
realist growth project given like continu impact
oper leverag next year
recent data off-set counter-detail eas y/i compar
past state physician
would one character risk respons either/or
volum shift post recent neg data
fda/cm data public specif relat
agenc view data support
ce mark ecp expand cardiac power cathet management expect
first patient end
short interest float
discoveri platform scientif expertis
think opportun treat
distinct posit develop novel therapeut treat
soft inhibitor profil differenti
make uniqu therapeut target
inhibit effect treat inflamm
levarag discoveri platform develop
uniqu develop program
develop possibl use
believ enabl drug succeed attempt
inhibit fail
abil inhibit itk complement
uniqu profil reflect phase result
inhibitori abil treat inflammatori diseas
announc earlier year result inform
advantag itk inhibit add profil
expect phase readout rheumatoid arthriti ra
ind file topic soft jak inhibitor
initi phase trial ra
top-line readout phase ra trial
initi phase trial second indic
initi phase trial
file ind inhibitor
short interest float
part new market strategi work
think gocovri sale
part get traction yet
invest less regard market spend
think potenti bd partnership
updat regard pipelin gocovri multipl sclerosi
ms walk partial onset seizur
talk chang payer coverag gocovri
biggest disconnect among physician patient
caregiv understand benefit gocovri
fda discuss phase result ms walk
short interest float
tam size market opportun
margin expans driver ebitda margin expans
segment product line growth rate adjac
could potenti grow
organ revenu growth guid mm
revenu ex acquisit impli organ growth
rate low end guid organ growth rate
conserv guidanc driver upsid
acquisit mckesson patient solut busi
advanc care hme busi estim
acquisit add mm revenu nearli guid
mm revenu acquisit shift strategi
still expect add mm acquisit revenu per year
result competit bid program summer
news flow around retail enter dme market
implement round contract price jan
quickli get recent acquisit run
rate ebitda margin comment technolog vs
competit bid dimension impact cmss
competit bid program product
impact abl pass price compress
supplier expect slow-down prior bid result
competit prevent amazon larg nation retail
take share market
balanc sheet anticip rais addit capit execut
 strategi
short interest float
talk reason confid tcr
discuss optim condit paramat
abl address solid tumor
talk hla restrict hurdl clinic
execut step adap taken ensur
discuss safeti platform strategi place
avoid toxic minim off-target bind cross reactiv
provid addit trial patient dose detail
earli solid tumor respons announc januari
interim futil registration-direct phase ii/iii trial evalu
synovi sarcoma myxoid/round cell liposarcoma mrcl
durabl updat phase synovi sarcoma respons
updat phase data
safeti respons data phase surpass trial evalu adp-
multipl solid tumor
initi clinic trial combin pathway inhibitor
think necessari gener respons avoid toxic
discuss manufactur capabl current
turnaround time patient futur plan expans
short interest float
excit iga nephropathi igan
data investor expect year
investor think read-through emd serono
atacicept igan differenti
recent receiv mileston merck agonist
start trial single-ag deliv intra-
vesic bcg-refractori non-muscl invas bladder cancer
select indic
still confid benefit squamou cell
carcinoma head neck scchn talk
dose regimen select rational behind
program investor excit program
part collabor novarti requir help fund
could transform aduro pivot oncolog
compani one asset kidney diseas priorit
focu invest across program
collabor novarti sting agonist head
pull sting agonist portfolio
healthi volunt biomark data
patient data iga nephropathi
interim data keytruda squamou cell carcinoma
head neck scchn
pivot trial includ one carri forward sole
aduro well reimburs aduro prior earli stage cost
give detail novarti oblig claus well
level input novarti would pivot trial studi design
short interest float
result first two optic trial cohort show patient
steroid common use steroid eyedrop
treat higher dose requir rescu anti-vegf inject
dose-respons lower-dos cohort could discuss
efficaci seen higher dose cohort import
dose respons regul
think ahead design potenti pivot trial
anticip demonstr non-inferior standard
care think stabil vision vs
think improv central subfield
potenti improv vision patient stabl anti-vegf
thick vs improv best correct visual acuiti
measur efficaci use real-world practic
view market gene therapi intravitr
inflamm seen first two cohort treat
inject compar subretin inject
cohort manag steroid eye
drop could talk well-control inflamm
first two cohort length time need maintain
learn wet trial bring studi
diabet retinopathi expect dose
util clinic trial design similar across trial
complet enrol cohort optic studi wet
cohort updat phase optic
short interest float
repres dr ceo gregori gin head ir
initi data nk engag phase
begun enrol patietn trial egfr nk
redirect studi still track read later year
engag efficaci data studi avail
assumpt around respons rate durat
enrol patient tumor known express
respons patient number could support acceler
egfr specif screen
approv file mycosi fungoid
expect see benefit patient lack egfr
price assumpt rel drug
approv mf
ultim indic combin believ
rational support combin nk
greatest potenti patient benefit
cell advantag see nk-engag adopt nk
announc select two new preclinci nk-engag
cell nk approach patient indic
program excit target
believ would suitabl approach
learn and/or genentech collbor
initi data trial t-mf
safeti preliminari efficaci data egfr tumor
short interest float
comment tibsovo uptak opportun acut myeloid
describ mitapivat opportun thalassemia
leukemia aml opportun amidst perceiv grow
think pivot develop strategi thalassemia
competit venetoclax
rational behind next-gener pkr activ
describ tibsovo expans opportun
vs mitapivat plan posit next-gener
drug clinic develop
expect upcom proof-of-concept data
mitapivat sickl cell diseas would success
initi proof-of-concept data phase trial sickl cell diseas european
phase mitapivat data thalassemia eha
ind clearanc initi fih studi healthi volunt
data phase activ activate-t trial pkd patient
potenti snda tibsovo cholangiocarcinoma
short interest float
elabor role rasp reactiv aldehyd speci
describ program allerg conjunct bar
mechan ocular system inflammatori diseas
efficaci phase invigor trial product
reproxalap differenti standard care dri
differentit current therapi
updat us dri eye program data releas back
novemb mix posit symptom posit
could talk pro con phase allergen
chamber trial novel methodolog
fda view work
sign go
efficaci bar hope meet
updat us work new formul
phase guard trial part prolif vitreoretinopathi
capit need
initi phase renew studi reproxalap dri eye diseas
phase sad/mad clinic trial result
short interest float
decid commercial/pr strategi danicopan
diseas area find promis bd
much price pressur anticip franchis
effort increas revenu diversif
next year inevit price come
alexion ever consid institut dividend way
primarili focu complement futur
adjac therapeut area interest
much pnh franchis anticip cede
result futur competit
much opportun barth syndrom might
make partnership decis stealth
return capit sharehold potenti indic confid
revenu tail
beyond fcrn emerg therapeut modal
appear interest excit bd perspect
compar contrast level enthusiasm
strateg rational develop
initi dose-rang studi ultomiri hsct-tma
announc phase result bridg trial ultomiri pnh
full phase trial enrol wilson diseas
initi dose-select ph studi al amyloidosi
initi danicopan phase studi
short interest float
talk push/pul base manufactur royalti
elabor big pictur plan build
chang strategi vivitrol aristada
rodin acquisit vision
talk prepar launch
franchis see data help justifi deal
schizophrenia bipolar happen
provid updat regard restructur plan cost save
chang approach launch later year
progress far
expect key efficaci data
think bd
know someth excit
schizophrenia bipolar disord pdufa date
short interest float
guidanc project increas revenu
abl maintain tight price band onpattro
see patient growth come onpattro
continu move new geographi expect similar
expect see granular detail onpattro
givlaari lumasiran launch
launch region region basi
could comment progress made regeneron
launch tafamadi ttr-cm us chang
partnership made date could expect see first
way compani look total market opportun
data collabor timelin enter
reflect number givlaari start form submit
strong project revenu growth slow opex growth
potenti revenu appropri compar givlaari
previous comment would year peak
start form receiv first week
loss could provid detail potenti path
profit whether would expect trend continu
present phase lumasiran result illuminate-a oxaleurop
intern congress amsterdam netherland
top-line result illuminate-b phase trial pediatr primari
ema approv givosiran acut hapat porphyria
fda approv lumasiran
beyond
short interest float
latest feedback fda decis
way could drive ferahem growth
could process timelin surround potenti
latest coagulomet ciraparantag
remov makena market
studi clear
anticip divestitur intrarosa vyleesi
enrol on-going phase
occur think divestitur term
potenti econom
think growth ferahem
could competit impact monoferr
anticip divestitur women asset intrarosa vyleesi
initi phase trial ciraparantag
top-lin data phase ciraparantag
fda rule makena approv
short interest float
expand cv outcom label vascepa
increas sale market effort
notabl formulari coverag chang
anticip sale ramp progress
compani feel strength case follow
could eu approv vascepa come
patent litig trial decis judg
think market size price eu rel us
appetit busi develop leverag
far along sale forc target current
vascepa salesforc addit product
could help us understand ad invest dtc
advertis extent could continu
patent litig trial decis vascepa
short interest float
big eb market term patient number
see potenti market posit among
unmet need
competitor develop
what mechan action data
potenti growth opportun juxtapid
gener far
myalept current approv indic
learn amicu fail eb studi
line extens opportun explor exist
incopor trial
take away unblind interim analysi
phase data epidermolysi bullosa eb
phase data lojuxta famili chylomicronemia syndrom fc
short interest float
talk nmda moa broadli look data
talk opportun parkinson cognit
recent trial know still know
impair risk trial popul
discuss regulatori hurdl novel moa pain indic
hypothesi work ptsd
path forward look like advanc dpn
seem like challeng indic target
confid efficaci could dial
commerci strategi go alon partner right time
updat two phase studi initi
advanc dpn fibromyalgia start late
bar efficaci studi
program
capit need beyond
data phase studi pain dpn
data phase studi ptsd
data phase studi fibromyalgia
data phase studi parkinson cognit impair
short interest float
briefli discuss rational recent disclos phase studi evalu nsclc
compar anti-tigit compound mechanist perspect well develop perspect
think azn prune develop program egfrm nsclc continu develop
program decis impact
describ type anti-tumor respons see thu far term time respons depth respons
tumor type see best respons anecdot cohort excit term clinic benefit
commerci opportun
describ on-going trial design might provid us random data
import believ fc compet determin clinic benefit anti-tigit antibodi
phase expans data multipl solid tumor type
phase dose escal trial result pancreat cancer
phase expans data tnbc
phase trial intiat nsclc
short interest float
expect nda submiss tenapanor
latest think washington time
hyperphosphatemia indic data leverag
includ oral-onli drug dialysi bundl
ibs-c applic file
look term timelin tenapanor
type market develop pre-commerci
develop japan china canada
activit undertak
think potenti us partnership ibs-c
larg commerci footprint requir order market
tenapanor hyperphosphatemia
potenti hyperkalemia
nda file tenapanor hyperphophatemia
potenti fda approv tenapanor hyperphophatemia
short interest float
could tell us bit expand collabor beacon
give confid etrasimod could success atop
discoveri format neurosci
dermat ad would fit ad treatment landscap
main differ etrasimod modul
trial design advis might expect see
like ozanimod might impact label
data
track complet elev enrol
briefli recap olorinab data inflammatori bowel diseas
anticip differ enrol pace elev
approach crohn diseas cd differ one
rational behind pursu irrit bowel syndrom ib pain
took data ulcer coliti uc
trial olorinab instead ibd also assess ibd
phase data decompens heart failur dhf
olorinab phase captiv data ib pain
etrasimod phase advis data atop dermatitis/ad
etrasimod phase cultiv data cd
etrasimod phase data alopecia areata aa
etrasimod phase elev data uc
etrasimod phase data eosinophil esophagitis/eo
phase data decompens heart failure/dhf
short interest float
see height flight transcon hgh
difficult endpoint composit endpoint
simpl titrat transcon hgh minim igf-
natpara shown transcon pth compar
excurs observ flight
could expect see ole data fix dose
envis challeng manag level real
data report
world among patient switch transcon hgh daili growth
mani center sophist enough manag
appropri switch transcon hgh
could expedit path forward transcon pth base
fda recent publish draft guidanc
kind differ could expect transcon cnp
sustain deliveri compar bmrn op pulsatil
could expect see transcon pth
transcon pth phase path forward data hypoparathyroid
transcon hgh phase adult studi initi growth hormon defici
transcon hgh bla file growth hormon defici
transcon pth phase open label extens data hypoparathyroid
transcon hgh file growth hormon defici
transcon hgh phase ped initi japan growth hormon defici
transcon pth phase initi hypoparathyroid
transcon phase studi initi china achondroplasia
short interest float
follow failur previou lead program varlitinib pan-her
discuss atop dermat competit landscap
inhibitor discuss new strateg focu compani
fit within landscap
introduc receptor inhibitor
statu help set investor
discuss scientif rational use
expect dose escal data earli
receptor inhibitor atop dermat asthma
talk current cash posit runway
interim dose escal data receptor inhibitor atop
dermat earli
complet dose escal receptor inhibitor atop
dermat
short interest float
sens long consolid therapi
qualit describ natur increment data
requir suffici deplet cccdna level produc function
updat expect see particularli easl
anticip disclos durat consolid
basi cutoff use measur
provid color tenor pace
pgrna make confid level provid
meaing evid cccdna deplet
discuss regul therapi stop rule
thought compet strategi use tripl
factor consid determin optim
treatment durat consolid therapi
therapi includ hbv rnai expect clinic
effect compar efficaci safeti nuc core inhibitor
updat data phase trial hbv-infect subject
phase data present post-withdraw virolog respons
interim phase data readout
short interest float
head ir
current see growth tagrisso
imfinzi fit competit i/o space
meaning threat tagrisso domin egfrm nsclc
see growth opportun us row
maintain lynparza lead posit best
strateg view i/o combin regimen
parp given competitor also expand frontlin ovarian
develop tremelizumab
cancer prostat cancer
calquenc launch progress cll
view enhertu opportun could potenti
demograph cll patient get drug
best-in-class therapi malign
data phase danub imfinzi treme/imfinzi/soc bladder cancer
data phase kestrel data imfinzi/ imfinzi treme/ soc head neck
cancer
multipl enhertu data present gastric nsclc
lynparza approv broad ovarian cancer mainten
lynparza approv hrr mcrpc profound trial
tezepelumab phase data navig trial sever asthma
short interest float
analyst daniel antalffi medic suppli devic
sale growth actual acceler comp-adjust basi
vs would growth deceler within
rang vs toward low end
specif part busi lose
momentum conservat
 patient go cardiac surgeri
afib yet patient treat
atrc strategi continu deepli penetr fast-
given converg superior trial bogey
recurr rate clinician order drive adopt
anticip pma approv late time frame
go-to-market strategi converg procedur
one think potenti ramp could converg
watchman-lik ramp slower could key
barrier adopt
sustain growth profil busi
open ablat mi atriclip biggest risk
achiev growth profil
strategi behind sentreheart acquisit
specif complementari synergist exist
busi mileston tie increment sale
price well-fund meet mileston
sentreheart acquisit push profit
realist pathway achiev sustain profit
data releas converg trial data-readout expect hr heart rhythm
societi scientif session may w/ fda panel approv year-end
fda submiss fda data submsssion amaz trial lariat expect
approv
trial enrol continu enrol deep-af trial site
enrol ice-afib trial site
short interest float
ln aurora data show
pre-nda meet taken place given roll
see voclosporin market opportun potenti
nda likelihood submiss vs
cheaper cyclosporin avail
updat voclosporin ophthalm solut vo de
voclosporin ip
may downtitr voclosporin help outcom lupu
investor expect similar breakdown respons rate
base downtitr aurora
like outlicensing/non-dilut financ
updat new guidanc focal segment glomerulosclerosi
strategi facili enrol program
fsg given intensifi competit
voclosporin pre-nda meet lupu nephriti
voclosporin nda submiss lupu nephriti
voclosporin phase audrey top-line result dri eye syndrom
voclosporin phase interim data focal segment glomerulosclerosi
short interest float
pharm svp cbo head strateg financ jason fredett vice-president ir
describ type increment data
compar contrast similar differ
expect see
term structur moa
import demonstr muscl benefit
help us better understand initi data suggest
registr prospect
better improv wherea better
describ natur qualiti discuss
measur biolog activ
fda regard trial design timelin potenti
axcella protect ip particularli regard composit
registr studi
matter method use emm given heterogen
composit divers mechan action
top-lin phase data hepat encephalopathi
ind decis hepat encephalopathi
top-lin data studi nafld
initi non-ind studi sickl cell diseas
ind decis and/or nash
short interest float
analyst richard newitt medic suppli devic
reason think axgn revenue growth guidanc
base case investor expect potenti
upsid revenue growth deceler reflect
growth curv structur consider
could deceler relat challeng convert
prospect user move past earli adopt
taken respect busi segment
think rep product beyond
expect breast reconstruct neurot brn
expand new center expect timelin
sensation-now sense-ii trial statu
reimburs resens technique/procedur
timelin expect surgic manag pain
type impact expect see new
regard launch/rev contribut preliminari data
product use deriv initi market oppti
initi impact refocus rep resourc
compani core trauma market expect similar type step
reimburs rule allograft use asc outpati
surgeri expect materi impact
impact seen if/when privat payor adopt similar rule
axoguard nerv cap launch stump neuroma pain expect feb
short interest float
analyst daniel antalffi medic suppli devic
base pre-announce appear r-snm launch
histor low rate presenc newer technolog
go well physician adopt technolog
alter penetr rate ex-u countri
trial physician switch wholesal
competitor launch next-gen product
physician major implant
combat competit counter-d
mani train use r-snm physician
continu strengthen posit overal continu
yet adopt technolog despit rep coverag
gain share light potenti compar competit
rational
product beyond competit technolog
total address market sacral
neuromodul indic key obstacl
revenu run rate manag would expect
realiz product innov
achiev sustain profit cash burn rate
brought forth chang potenti penetr rel
quarter launch
product pipelin next-gener product pipelin non-recharg
devic compat lead
short interest float
anticip readout intial six-month data first
meaning chang biomark seen far
two patient enrol cohort sunrise-pd studi
gangliosidosi clinic trial expect see
expect cohort month compar
granular data patient six month followup
gangliosidosi rare diseas could
data present parkinson diseas focus updr
say expect pace recruit
score could discuss signific endpoint
studi year
meaning endpoint context pd
part spin-out legaci small molecul portfolio
see path approv axo-lenti-pd
acquir prefer equiti stake arvel
outcom measur could consid absolut win
could talk view asset could
parkinson potenti approv pathway factor
mean balanc sheet
interim cohort readout axo-lenti-pd huntington diseas
data updat patient treat gangliosidosi
initi trial gangliosidosi
short interest float
expect trd data
explain opportun narcolepsi
path forward look like depress trd
phase studi posit
think commerci strategi major
path forward look like acut migrain
commerci plan given mani new product
product differenti competitor op
recent bd deal could explain
rational behind benefit opportun
one thing believ underappreci
compani
elabor hope see alzheim
agit studi come
phase intercept studi readout acut migrian
phase stride studi readout treatment-resist depress trd
phase advanc studi readout alzheim agit
short interest float
analyst daniel antalffi medic suppli devic
januari pre-announce strong rel
surpisingli guid oper margin
street seemingli intern expect driver
lrp chang vs issuanc
out-performance
specif medic deliveri pain point
organ sale growth exceed
intiti lrp guidanc impli chang
guidanc key driver
increment margin expans
expect busi stabil right
bax updat thought capit deploy
way think about/what factor drive go-forward
prioriti much will lever quickli
aggress deploy capit rel last year
relat constant currenc sale growth guidanc
statu intern investig
key put take specif
implement implement improv accuraci
deceler vs oper sale growth deliv
reliabl financi report go forward
potenti impact coronaviru
short interest float
feel like momentum actual build across
product launch point-of-car solut periton dialysi pd expect
version launch time-frame
product launch launch theranova time-frame
product launch new pump platform larg volum syring
ambulatori pca pump expect launch juli
updat complet intern investig
becton dickinson compani
analyst richard newitt medic suppli devic
key factor would result hit upper lower end
offer incent custom prevent
cc revenue growth outlook
updat around alari remedi
requir convers fda
submiss progress still expect
submiss expect approv relaunch
date clariti qualifi medic necess sale
much revenu contribut expect
give management confid alari situat wont weaken
compani competit posit and/or potenti make
compani suscept share loss pump categori go
purchas competitor pump might loss pump capit
sale impact consum sale growth trend go forward
convers progress fda lutonix
below-the-kne btk compani plan file
supplement data fda expect see continu
momentum dcb sale
give management confid updat price headwind china
vs prior due volume-bas price
right level management arriv headwind
assumpt coronaviru qtr
alari infus submiss pre-marketing submiss expect
short interest float
could elabor role receptor chronic cough
hope term clinic meaning
lead asset differenti chronic cough vs
efficaci upcom phase readout
bayer shionogi product also high select
talk much tast side effect chronic cough
elabor indic explor
link mechan hypersensit
cough chronic pruritu associ atop dermat
could elabor potenti market opportun chronic cough
patient identifi treat
capit need
phase relief top-line data chronic cough
start phase studi chronic pruritu associ atop
dermat
short interest float
christin head strategi ir
could talk discoveri platform success
updat phase studi that partner
make platform uniqu term identifi drug candid
op
could differenti anti-abeta
see neurodegenr diseas therapi evolv
antibodi thought latest aducanumab
futur role biomark play develop new
thought far efficaci
capit need
subgroup phase studi implic
phase
data present intern congress april
start phase prevent studi preclin alzheim diseas
data readout confirmatori phase studi clariti ad
short interest float
latest thought commerci strategi
physician indic concern satur
rimegep regard go alon strategi commerci
cgrp receptor use inject cgrp plu oral cgrp
view
view oral cgrp market opportun
talk discuss payer far
rimegep studi acut
prevent treatment migrian
import migrain prevent data rimegep
differenti competitor space
could elabor on-going opportun
troriluzol given recent fail anxieti trial
updat trial design/approach al verdiperstat
plan futur bd diversifi portfolio
rimegep phase migrain prevent readout
rimegep acut migrain pdufa
troriluzol obsess compuls disord ocd phase readout
complet troriluzol phase studi alzheim diseas
short interest float
offic act cfo geoff nichol svp head global clinic
requir acceler approv valrox
investig stray protocol
much patient profil done understand
patient less like adopt gene therapi hem
hemlibra launch well much anticip
result inadequ prophlaxi steroid sub-par
vosoritid address unmet medic need
valrox compet hemlibra vs factor replac
vosoritid much competit threat see
hemlibra influenc price strategi launch
longer act analogu develop
develop trajectori news flow
peopl miss question adopt valrox
decid upon hereditari angioedema next
profil isnt predict would like
area gene therapi
valrox post-bla submiss updat hemophilia februari
phase phearless trial initit pku
valrox phase vg/kg vg/kg data hemophilia
valrox phase vg/kg data hemophilia
vosoritid nda/maa file achondroplasia
vosoritid studi initi dominantli inherit short statur
short interest float
see data inest neo-antigen person vaccin
larg portfolio platform program believ
investor expect learn data
underappreci
genentech manag recent investor day said
plan share data
observ impress cell respons inest could still
describ program hope learn
better plan improv
initi dataset
new fixvac public
discuss carvac approach could use
envis inest fixvac vaccin fit
address shortcom current car-t therapi
treatment paradigm melanoma
believ capabl invest requir
april initi immunogen safeti clinic data inest /-
tecentriq pt combo pt single-ag metastat solid tumor
may also includ data neo-adjuv triple-neg breast cancer tnbc
immunogen data tnbc select antigen
public updat detail data fixvac vaccin
updat data fixvac adjuv melanoma
data intratumor solid tumor
initi data
random trial inest plu keytruda melanoma
short interest float
analyst puneet souda life scienc tool diagnost
exosomedx bill began decemb epi
geograph outlook outlook china/eu/
discuss earli experi go market strategi
america china grew sustain post
product natur current sale team
eu trend follow us
cell gene therapi build manufactur
biopharma academ end market shape
facil gmp protein gt expect start
growth margin expect youv discuss
gener revenu demand expect year
revenu target lt organ revenu growth
protein simpl uniqu protein simpl
platform havent seen competitor space
overal demand platform drive
convict expect margin
exosom dx epi roll-out lcd place
 gt manufacutr facil complet
short interest float
expect speed zynteglo launch europ
payor respond value-bas payment plan
countri expect commerci sale year mani patient
differ feedback eu us payor
could potenti treat manfactur capac
view bcma landscap think best-
expect clariti anticip file timelin sickl cell diseas
in-class anti-bcma therapi could emerg see market share
year compani view potenti acceler
approv surrog biomark posit lentiglobin updat
expect three approv product
affect project rate cash burn go expens
opportun price discrimin zynteglo tdt
expect increas ramp launch cost
lentiglobin scd opportun differenti price
alreadi bake current opex project
eu us
excit earli stage pipelin
timelin expect new asset clinic
bla file ide-cel relapsed/refractori multipl myeloma
first commerci patient treat zynteglo
complet roll bla submiss zynteglo -thalassemia
launch zynteglo uk franc itali
regulatori submiss lenti-d cerebr adrenoleukodystrophi
short interest float
expect next updat ret inhibitor
comment expect upcom voyag
pralsetinib think chanc better lilli ret
data ayvakit gist expect control
drug expect lilli label
arm function
pathway forward indol system mastocytosi
elucid acquir solvent front resist ret-driven
ism becom appar
malign discuss view ret resist
mechan potenti could resist impact
comment ayvakit commerci launch feedback
payor anticip gross net gist
intrigu next-gener egfr inhibitor
comment ration seri new compound
expect proof-of-concept data
nda submiss pralsetinib ret fusion posit nsclc
updat avapritinib data part phase pioneer trial indol system
mastocytosi ism march
nda submiss pralsetinib ret-mut mtc
broad updat pralsetinib ret driven malign
top-lin data phase voyag ayvakit vs stivarga gist earli
potenti pdufa extens avapritinib gist
short interest float
analyst daniel antalffi medic suppli devic
drove sale shortfal dynam inform organ sale growth guidanc obvious sale guidanc rang
wider year year past beyond given miss anyth chang meaning approach guidanc
develop sinc manag provid organ sale growth guidanc time-frame includ scope data
ischemia trial miss guidanc still viabl key driver chang
specif relat recent area weak icd ep nearli major player report result much is/ha bsx-
specif vs underli shift market dynam quickli busi stabilize/reacceler
btg acquisit progress btg bring strateg addit increment track toward
cost sale synergi youv target
regard new product launch exalt-d lotu quickli product ramp key barrier adopt rep face earli launch
beyond exalt-d lotu key pipelin product next year secur sustain top-tier sale growth profil
posit margin expans perspect driver increment margin expans
data readout scope trial estim studi complet data readout
septemb
fda approv asses watchman devic patient unsuit oral
anticoagul expect fda approv
product launch ranger dcb drug-coat balloon expect launch
expect launch time-frame
short interest float
launch tafamidi ttr-cm color view
prepar potenti launch infigratinib come
ttr market opportun
along could describ step compani take
favor compar tafamidi cross-trial basi
build commerci footprint ahead approv
month treatment go forward outcom measur
think opportun infigratinib
would indic superior treatment profil ttr-cm
cholangiocarcinoma cca bladder cancer compar
six-minut walk test potenti approv endpoint
opportun achondroplasia
ttr-cm could discuss approv
pipelin priorit whole select
endpoint would mean label initi data could
asset bring clinic balanc indic
supplement long-term outcom data
orphan diseas indic larger opportun
nda submiss infigratinib cholangiocarcinoma cca
top-line data readout phase trial patidegib gel gorlin syndrom
interim updat phase ii ole trial ttr-cardiomyopathi
data present phase ii trial recess dystroph
complet submiss roll nda applic molybdenum
ind submiss congenit adren hyperplasia
short interest float
view evolv rcc landscap
discuss consider time clinic execut
see telaglenastat glutaminas inhibitor potenti posit
term enrol first line lung cancer studi
landscap
discuss arginas inhibitor partner
reason confid posit cantata
compar target ido next step
program
discuss rational evalu telaglenastat
color statu small molecul inhibitor
look potenti partner
phase ii cantata top-lin data expect
initi random phase ii trial telaglenastat nsclc patient genet
mutat
phase ib studi cystic fibrosi patient expect start enrol
potenti partnership discuss around small molecul inhibitor
determin next step time clinic trial
short interest float
analyst daniel antalffi medic suppli devic
result deliv consecut quarter
reimburs justifi support data lastli much
solid low-to-mid teen sale growth chang
flexibl adjust potenti reimburs cut
busi gener perform consist within
busi has/hav primari driver
anoth controversi impend competit coronari
lithrotripsi balloon product avail today europ
back half tailwind
physician util technolog coronari europ
headwindsthat could impact busi particularli y/i
 replac atherectomi complement atherectomi
compar get increasingli difficult
much risk exposur csii busi product like
one controversi surround right atherectomi
reimburs risk likelihood meaning
new product launch key csii long-term
reimburs chang year medium-term
sale guidanc risk-adjust long-term
atherectomi seem fairli well reimburs level
guidanc new product sale
much new product contribut sale today
studi completion/data readout estim complet
studi estim studi complet eclips trial
short interest float
analyst puneet souda life scienc tool diagnost
reimburs commerci payer plan
pipelin squamou cell carcinoma scc suspici
anoth commerci year book limit competit
pigment lesion spl assay expect launch
thing chang local coverag determin
data readout expect timelin
lcd medicar rate place
commerci ramp follow launch lesson learn
price advanc diagnost laboratori test
ddx-m would appli
price affect commerci payer accept
price price
sale team could elabor sale team add
stand current sale team expect
add
consider revenu adjust
discuss natur adjust expect
short interest float
softgel oral current health
oral specialti deliveri base growth small
softgel oral solid market us could break
molecul suppli busi breakdown clinic
growth consum health beauti pharma busi
asset commerci drug could discuss zydi
biolog development pipelin look like
biolog robust growth weve seen recent year
paragon paragon integr go
custom demand look like gene therapi end
enough manufactur suit meet demand
oral dissolv tablet busi opportun next
 leverag leverag current
expect trend time given increas leverag
expect larg tabl
revenu growth outlook busi
paragon integr revenu ramp
capac expans bloomington madis facilti
roll drug substanc headwind next quarter
commerci custom brought board
short interest float
though saw respons think trial biweekli
differ optimab process discount
dose aml/md respons durabl
respons patient lower-risk diseas
continu believ potenti without pre-
confid orr pr
allogen cell therapi folfox
combin might improv efficaci dose cyad-
think alloshrink trial observ
correl dose respons think
tell proceed program
data cell manufactur optimab
help us understand plan includ
shrna knockdown mica/micb program
two uniqu approach produc allogen tim
tcr inhibitori molecul express shrna knockdown
believ approach better
employ competitor
believ shrna knockdown result
persist knockout target
focu day ny next month
data three addit r/r mcrc patient allogen
alloshrink
preliminari data expans cohort ph deplethink
think trial r/r aml/md
initi data ph dose-escal trial
knockdown mica micb r/r aml/md
short interest float
strategi ir offic
analyst puneet souda life scienc tool diagnost
pharma agreement pipelin ad pharma
competit global expans look
partner addit expect
expand presenc global view
perform stack vs expect
competit landscap differenti
outlook backdrop revenu growth
look grow us
guid expect shape biggest
margin expans lumpi revenu high margin pharma
driver upside/downsid
nipt non-invas pre-nat test nipt signific part
portfolio impact margin
long-term outlook nipt
payment creat margin fluctuat think
long-term gross margin cadenc compani
short interest float
recap advoc data
assum posit outcom think
gti instrument come well-public
trial design
among aav-treat physician
need address entir fsg
readthrough advoc
accolad
indic contempl
accolad chi expect
rare less rare program advanc
post-shin studi give confid aurora trial
biolog rational fsg
investor think avacopan price
phase focal segment glomerulosclerosi fsg data
avacopan phase aurora hidraden suppurativa hs data
avacopan phase accolad glomerulopathi data
phase fsg data
avacopan nda/maa submiss anca-associ vascul aav
short interest float
comment dynam parp inhibitor market
comment rubraca opportun prostat cancer given
ovarian cancer sever agent move
rubraca competit agent regulatori
key attribut rubraca differenti drug
highlight clinic develop lucitanib
competitor
see primari partner asset
review rubraca ex-u opportun see
recent acquir radiotherapi asset
launch activ multipl eu countri
rational behind acquisit develop
potenti approv rubraca brca mcrpc may
phase rubraca/lucitanib advanc ovarian cancer
present phase lucitanib/opdivo data advanc cancer
short interest float
comput program system inc
talk benefit saw favor
see upsid long-term margin target
would factor drive
small hospit space etc
talk strategi sell trubridg outsid
talk drive confid behind new
ehr base valu prop vs exist ehr vendor
growth target recur revenu
drove book improv vs what
walk us near-term impact on-going shift
expect book near term go forward
saa licens model longer term impact
provid color traction get health see
thought capit alloc strategi
nation healthcar system could rehash
youv reach net leverag target
potenti adjac market
short interest float
puts/tak contempl management guid cc org
revenue growth room potenti upsid potenti new
product launch contempl hsd rang mani new
product launch expect
salesforc expans effort addit channel chang
progress management seen materi impact team us
surg ou implement initi
level product increas expect see
busi implement chang us
ortho busi progress still expect revenu growth
acceler factor could delay initi
contempl management guidanc
potenti new product launch expect aao march
investor think buffalo filter bf revenue growth
seen impact bf revenue state legisl
around smoke evacu colorado rhode island awar
addit state legisl progress
lever could propel gm impli
op margin improv year think
gm/op margin expans lt much potenti
accret integr mfg cnmd main op gm
expect complet
mgmt strategi reason think cnmd
ortho divis could prioriti given recent acquisit
gen surg particular deal size investor keep
short interest float
cosmo own siginific share cassiopea redhil what
unmet need procedur sedat
long-term vision compani
byfavo address
big market opportun aemcolo travel
lot product revolv around colonoscopi
diarrhea differenti current treatment
procedur see market evolv advent
regulatori pathway methylen mmx
could discuss new cancer drug candid cb-
data need show
mechan action tumor type
april potenti fda approv byfavo procedur sedat
august potenti fda approv winlevi acn
phase data aemcolo ibs-d
could work
short interest float
market opportun acromegali well-
could expect data strategi updat
establish market
patient segment target big
pros/con pursu paltusotin acromegali
net vs paltusotin acromegali net
would need see pursu net
seen preclin studi agonist
acth antagonist
short interest float
trial design goal evolv edg
trial enrol expect data
much enthusiasm detect differ
acromegali patient segment oral altern inject
think lead market first
phase data develop strategi updat neuroendocrin tumor
net
oral agonist phase initi hyperinsulinemia
acth antagonist phase initi cush diseas
analyst puneet souda life scienc tool diagnost
result pre-announc consensu top line
cryogen cryogen integr progress
estim put take quarter
expect cryogen revenu
think compani rebound
biostorag market grow acquisit creat
commerci therapi would character demand
opportun
exist commerci therapi type growth expect
car-t reimburs announc coverag car-t cell
next year much new commerci
therapi provid rem facil august
impact busi what done improv
clinic trial pipelin cyrx share clinic
pipelin trend past year put take
phase would estim clinic penetr
cell gene therapi gt approv pipelin submiss
zynteglo eu roll
short interest float
learn far interfac hepat
investor expect updat potenti path forward
observ seladelpar
seladelpar primari biliari cholang pbc
possibl may pick initi
expect util current cash balanc
short interest float
chief staff execut committe michel katz senior director ir
vision medidata part dassault
see mdso target audienc product offer evolv
system meaning chang arc acceler
timelin given deeper pocket
come year
talk combin product offer medidata
could updat us integr long-term
strategi integr put take
give us updat acorn ai cross-sponsor slinic data
talk competit landscap differenti
build top line growth next five year driver
seen crowd play field expand
point non-ifr margin expans
short interest float
could remind us uniqu epicutan immunotherapi
base clinic experi believ
epit approach differenti
like treatment durat viaskin peanut
oit approv envis peanut allergi
revisit pepit data readout
treatment paradigm evolv viaskin peanut enter market
see long-term follow-up peopl
commer strategi us
could remind us studi design enrol statu
epitop design differ pepit
begun build commerci team ahead
work introduc ideal viaskin patch
possibl launch back half year
adult would character market opportun
children adolesc adult
term safeti efficaci see viaskin
milk studi step cow milk allergi program
viaskin peanut phase epitop part data peanut allergi
viaskin peanut fda adcom peanut allergi
viaskin peanut fda approv us launch peanut allergi
viaskin peanut ema file peanut allergi
short interest float
approv ripretinib gist expect immin
ripretinib opportun diseas
discuss gist market size key commerci lever
comment differenti properti
competit agent ad nccn guidelin
see competit field drug potenti
market year
ripretinib gist enrol expect complet
decis increas sampl size comment
rational increas sampl size
highlight pipelin asset excit
potenti approv ripretinib gist base invictu trial
complet enrol ripretinib phase intrigu trial gist
updat phase data tgct patient
updat phase trial rebastinib combin carboplatin paclitaxel
potenti ripretinib data phase intrigu trial gist
short interest float
moder puneet souda life scienc tool
non-melanoma product dermtech commerci product
coverag pla mean busi go
focu non-melanoma skin cancer inflammatori diseas
market compar pigment lesion
pigment lesion assay pla dermtech pla
melanoma workup walk us workup melanoma
compar option market
patient would dmtk pla order result
pigment lesion assay pla differenti dmtk
tell doctor
competit compet
busi combin discuss natur recent
busi combin mean dermtech
short interest float
meaning upcom open-label extens
preclin drug discoveri partnership intern
readout dcr-phxc trial design enrol
guidanc quickli candid move clinic
criteria close match pivot studi
could discuss asset whether tie
appear lumasiran first market primari
exist partnership could program potenti outlicens
hyperoxaluria type could talk bit develop
strategi context compet market singl
investor interest dcr-hbv differenti
compet rnai knockdown agent could talk
dcr-hbv identifi expect differ
develop extens partnership drug discoveri
competit preserv express gene
much spend compani resourc dedic
interim readout ole
report top-line phase data dcr-hbv hbv
complet enrol registr studi
short interest float
analyst daniel antalffi medic suppli devic
put take sale guidanc
base result clearli market share shift
global transcathet heart valv thv sale
 driver ew share gain
thv specif consecut quarter
sustain dynam market share dynam
underli sale growth driver deceler impli
guidanc across busi
biggest risk guidanc
number new center continu increas much
growth come new center vs exist one
mitral fell short expect guidanc show
strategi place reach center
signific adopt acceler acceler primarili
enough sustain recent growth momentum long-term
pascal europ meaning contributor
confid acceler given miss
chang either go-to-market strategi otherwis
would drive ramp particularli competitor gener
technolog continu roll clinic data
asymptomat sever aortic stenosi seem next potenti
place indic expans soon could becom
realiti key mileston watch ew progress
toward could expans asymptomat chang
earli tavr studi
ce mark/product launch expect harpoon mitral repair devic launch
product launch konect resilia aortic valv conduit expect
sutrafix expect late
short interest float
compani
view recent rinvoq upadacitinib launch
given strong presenc dupix ad market
rheumatoid arthritist ra potenti impact
see commerci opportun would posit
see oral jak fit current treatment
anti-il class grow take share
paradigm ad patient popul jak better address
dermatolog space view growth potenti taltz
compar biolog dupix
chang commerci strategi
olumi abrocitinib like file
ad given data seen far think
opportun olumi abrocitinib
trulic fda approv cv outcom label
solanezumab dian tu trial present aat-ad/pd
tirzepatid phase surpass data readout diabet
nda file olumi atop dermat us
mirikizumab phase data readout psoriasi
mirikizumab phase data readout ulcer coliti
short interest float
analyst richard newitt medic suppli devic
management view potenti upsid driver risk compani
management estim cheva market oppti
revenu guidanc factor impact quarterli
growth cadenc move year guidanc contempl declin
acceler hsd growth take elgx grow
market rate
give management confid ovat alto receiv fda eu
approv investor think alto revenu
contribut rel prior product launch first year
could alto propel elgx growth market rate
step need taken enrol complet
pma submiss fda confid management abil deliv
submiss timelin requir product
approv launch
investor think oppti long term
clinic present occur meaning could
data term acceler product utilization/adopt
regard partnership china product approv
pursu first involv parti approv process
expect launch china china aaa market
opportun compar us oppti
factor give management confid compani abl sustain less
cash burn per qtr average
compani stand restructur debt option
consid compani
studi intial submiss activ first view primari endpoint
cheva enrol initi enrol
nellix pma submiss initi submiss
short interest float
tazverik tazemetostat recent approv epithelioid
discuss rational behind safeti lead-in studi
sarcoma es ad nccn sarcoma guidelin
tazverik es fl expect
comment initi commerci progress
investor view broad opportun tazverik
comment portfolio expans opportun
excit
earli feedback clinician fl patient think
mutat diagnost test use clinician despit
like requir agenc
potenti tazverik approv follicular lymphoma fl june
complet safeti evalu tazemetostat combin doxorubicin
epithelioid sarcoma
complet safeti evalu tazemetostat combin rituxan
revlimid regimen fl
expand tazemetostat combin r-chop fl
initi combin studi tazemetostat enzalutamide/abirateron
initi clinic studi tazemetostat combin parp inhibitor
short interest float
look earli clinic readout
lesson learn competit readout
signal could signific opportun
acut gvhd agvhd past year
lupu nephriti histor graveyard fail
order expect three on-going trial
drug give confid succeed
read year
efficaci threshold see blockbust trial
biocon partnership give leg
believ go differenti
initi data equip phase studi uncontrol asthma
initi data equat phase agvhd agvhd
initi data equalis phase trial system lupu
initi data equalis phase trial lupu nephriti
short interest float
differenti factor biorphen vs current
given levothyroxin market larg oral solid
avail option think market
view opportun oral liquid formul
opportun product
compani plan multipl addit nda submiss
provid addit detail requir human
product like mayb
factor studi would timelin
talk unmet need product address
complet review
think commerci potenti product
expect econom bausch
think give confid
issu rais address
short interest float
physician feedback get jeuveau
indic launch first-of-its-kind program
could discuss aesthet label differenti
jeuveau price market strategi perspect
talk overal neurotoxin market evolut
strategi use innov market
evolux partner injector could explain
program benefit physician practic
could give us color upcom consum loyalti
program differenti botox loyalti program
updat itc litig could summar us
key point trial
us launch evolux program injector april
us launch custom loyalti program jeuveau
short interest float
patient result report
persist nk cell continu provid benefit
datapoint feel valid
debat would answer chang approach
overlook invest commun
note potenti protocol amend
mani investor expect updat data
process amend data
come data investor expect
includ patient treat amend protocol
biggest scientif risk biolog question
initi takeaway recent public
hope answer on-going trial
md car-nk result benchmark
on-going scientif debat whether nk cell therapi
give benefit day whether long-term
sever preclin dataset come half
investor look data
updat data aml mab diffus
updat data solid tumor
ph protect trial protmun
like initi data nk
short interest float
discuss optim outlook roxa approv
optimist abil roxa benefit
particularli ndd patient
tdapa design much flexibl roxa price
experi non-inferior margin
exist and/or without tdapa design
diabet drug time
provid updat your see term
strict ni margin anticip fda appli phase
pace enrol demand on-going phase ipf trial
ckd-anemia studi hif-ph inhibitor
help us better understand opt studi pam
view competitor purchas prv
vadadustat could impact commerci strategi
patient inelig declin soc therapi oppos
add-on therapi soc
phase trial initiaton pamrevlumab dmd
roxadustat file ckd-anemia
possibl roxadustat adcom ckd-anemia
pdufa data roxadustat ckd-anemia dec
short interest float
surpris phenomen activ magrolimab anti-
azacitidin myelodysplast syndrome/ acut myeloid
leukemia mds/aml translat learn
phagocytosi use develop broadli
higher-risk md discuss like threshold orr
dor support acceler approv magrolimab given
underli activ azacitadin alon
think data less impress
solid tumor approach could improv efficaci
magrolimab differenti competitor
suggest inactiv fc bind fcr increas
therapeut window opinion magrolimab
therapeut window dose limit set
advantag disadvantag target sirp
therapeut combin top list mds/aml
 instead
dlbcl oral azacitidin gem/ox acalaburtinib
believ macrolimab rituximab commerci
see risk move everi two week dose
competit secur acceler approv
think competit oral option mds/aml
expand efficaci updat durabl data magrolimab azacitidin
md aml
safeti efficaci magrolimab rituximab gem/ox dlbcl
safeti efficaci magrolimab atezolizumab aml
interim safeti efficaci magrolimab acalabrutinib dlbcl
initi safeti efficaci magrolimab atezolizumab bladder cancer
interim data magrolimab rituximab dlbcl registr enabl
short interest float
could tell us uniqu discoveri platform
reduct would need see progress
facioscapulohumer muscular dystrophi fshd
unmet medic need current standard care
identifi losmapimod potenti candid
treatment fshd
see studi updat muscl target
losmapimod trial
method action moa second canid fx-
seen preclin lend confid
move clinic
remain step toward ind file
engag fshd pt
target move forward develop year
could describ two trial losmapimod current
could recap recent announc collabor
underway endpoint assess
ind submiss hemoglobinopathi
short interest float
think filgotinib differenti label
think opportun filgotinib outsid
rinvoq approv us eu
given novel biolog toledo target
one-year head start think need
advantag pan- vs select toledo vs
close gap
chang new michel manto process
current cash level balanc sheet
put place success commerci eu
chang capit alloc strategi activ
filgotinib eu japanes approv ra
filgotinib us nda approv ra
filgotinib phase data readout ulcer coliti uc
phase data readout osteoarthr
toledo phase data readout uc
phase futil analysi idiopath pulmonari fibrosi ipf
mind
short interest float
data resolve-it trial initi expect
resolve-it success much overlap expect
provid detail around led delay
patient would target
chang studi protocol enrol
elafibranor compar oca
competit discuss indication-bas price
inclusion/exclus criteria phase resolve-it
commerci nonalcohol steatohepat nash
trial compar vs phase trial
primari biliari cholang pbc could potenti viabl
path elafibranor
nash market would plan commerci
think potenti need liver-biopsi
real-world commerci set diagnose/treat patient
see elafibranor fit treatment paradigm
nash prescribers/pay determin therapi
provid updat non-invas diagnost
kind uptak see clinic studi
result phase resolve-it studi elafibranor nash
initi phase studi elafibranor pbc
result phase studi nitazoxanid patient nash-
short interest float
advantag atla neo-antigen bioassay screen
think could similar situat iter
rel machin learn strategi
pioneer research area investor
competitor neon recent agre acquisit
skeptic atla find think best
distress price follow poor market reaction result
support advantag approach
neoantigen vaccin learn taken
investor look initi data part
talk neo-antigen cell therapi
trial signal want see move
includ advantag approach versu vaccin
forward larger trial
approach differenti competitor
genentech recent said expect neo-antigen vaccin
first phase develop signfic iter come
ind file neo-antigen cell therapi
part initi data neo-antigen vaccin
ph initi data
short interest float
increment spend fund
timelin zejula ovarian approv
save portfolio manag
guidelin updat give confid physician
complet recent phase trial
expect hiv doublet continu off-set eros
gsk bcma competit earlier line multipl
hiv triplet triumeq/tivicay gilead competit
myeloma known ocular toxic
growth outlook shingrix
attract gsk bi-specif deal
maintain price current level increas suppli
current trial design time
plan expand nucala label beyond asthma
capac and/or licens consum
mani elig patient encompass
nucala phase data nasal polyp
belantamab mafodotin approv mm
zejula approv ovarian
trelegi approv asthma
bintrafusp alfa phase data biliari tract cancer
short interest float
analyst richard newitt medic suppli devic
give management confid stabil us spine end-
market market rate contempl management guideanc
puts/tak contempl management revenue growth
guidanc room potenti upsid
fair assum dd y/i emerg tech et revenue growth still
expect above-market growth rate ex et much drag
consid biolog busi
factor consid mid ebitda margin outlook
much us core spine growth accel
attribut robot implant pull-through vs factor robot
instal base grow reason us core spine growth wouldnt
continu trend hsd potenti growth
accler dd
launch cadenc anticip new excelsiu
indic interbodi cranial modul imag platform
expect
expans toward reason level
would take ebitda margin expans toward upper
end rang
statu excelsiu robot knee applic
hear initi
grow dd see impact
manag chang sale rank
indic imag
short interest float
extent think improv pharmacolog could
updat strategi program
enabl better result fevipipr
could speak differ fevipipr studi
data expect studi pah
endpoint endpoint leda
moa take away recent
remind us data see leda
mad data report
interim need see interim final analysi
order decid move
would think po chronic rhinosinus
 chronic spontan urticaria csu program leda
success eosinophil asthma
hope show upcom analysi
could tell us bit program
collabor op came
phase leda interim analysi asthma
phase initi chronic spontan urticariacsu
phase data pulmonari arteri hypertension/pah
phase initi pulmonari arteri hypertension/pah
phase data ulcer colitis/uc
phase initi ulcer colitis/uc
phase leda top-line data asthma
phase titan top-line data chronic rhinosinusitis/cr
phase data solid tumor
short interest float
analyst puneet souda life scienc tool diagnost
follow expand lcd includ addit
readout recurr monitor market
cancer beyond lung expect chang
horizon what next expect data
indic like see impact near term
year much opportun gh vs pharma
expect top line benefit asp lift
expect tough compar growth
eclips readout expect late
expect gh grow percent
expect updat interim put take
increment growth come expand lcd
could drive earlier expect read
liquid first paradigm coverag expand what
comfort level among physician challeng tri
convinc adopt
data potenti american associ cancer research
american societi clinic oncolog aacr/asco march/may
short interest float
tritac platform compar bispecif
help set expect discuss efficaci measur
platform competit landscap willl small molecular
expect see interim phase data
concern cytokin releas syndrom toxic
discuss cytokin releas syndrom steroid util
t-cell engag bispecif antibodi class
studi
compar psma
discuss pro con
bispecif competit landscap
msln target help set expect phase i/ii data
provid color enrol progress
term dose escal
interim phase data prostat cancer medic
confer initi expans cohort
initi phase studi multipl myeloma
phase i/iia proof-of-concept data
initi phase studi
short interest float
could talk perform wage busi
outsid busi optim synergi impact
track expect time acquisit
revenu think cross-sel opportun
think near term headwinds/tailwind affect
trend recent sell season
wage side busi throughout migrat period
could talk earli traction saw small-to-mid
trend far vs expect
size employ market past sell season still earli
think margin opportun
inning vi vi wage acquisit
consolid hqy/wag biz abl return pre-
could give us updat transit
background rebecca whitehead incom
updat us progress youv made toward
wage acquisit synergi goal
short interest float
believ reason fda delay pdufa date
long act post-op pain market evolv
piec review believ
next year could peak sale
outstand fda standpoint
regulatori decis expect eu
talk address differ issu
canada larg market opportun rel us
brought give confid
issu address
soon could launch post-approv
market segment surgeri type like see fastest
expect arbitrag period cinvanti end
strategi rebuild sustol brand
expect product longer term
phase studi
chmp opinion
potenti canadian approv
short interest float
ph global head matthew beck execut director ir
highlight differenti properti proprietari
lead immuno-oncolog candid enter clinic
platform vaxwav therat vs vaccin
address cancer view opportun hb-
challeng current hiv/hbv vaccin
versu combin strategi
could vaxwav therat platform address challeng
hypothes mechan sequenti administr
elucid rational behind ad anoth arm hb-
cmv trial
expect safety/immunogen initi pre-empt
cohort preliminari efficaci data
would success dataset view
initi data phase cmv trial safeti reatogen data
ind clearanc treatment hpv cancer
initi data phase cmv trial pre-empt cohort month efficaci
post-transpl
hiv/hbv vaccin partner gilead phase initi
initi data phase trial hpv cancer later earli
potent either one alon
preclin model shown
short interest float
mcmean svp financ administr cfo moniqu koss manag
analyst puneet souda life scienc tool diagnost
outlook multipl guid down expect
ruo busi research use ruo busi post
benefit push project much push vs
lost expect pdp pdp move forward
breast cancer assay built strong team
strong growth expans product servic revenu
expect trend pipelin
look like much visibl new project
anticip assay expect inform
assay still pace earli launch fit
current standard care
posit what current cash posit follow
septemb rais prioriti longer term
relat invest high qualiti sustain growth
impact impact discontinu
sequenc advantag disadvantag
contract directli biopharma gone
pdp pdp updat follow disappoint
short interest float
analyst puneet souda life scienc tool diagnost
new product expect nextseq
acquisit focu pacbio rearview
valu proposit nextseq market
look util cash flow post termin fee long-read
nextseq flexibl
still target interest intern focu
guidanc guid growth
oncolog liquid biopsi market lbx market
expect given miss guid view
opportun accord guardant gh estim
conserv achiev guidanc that rel de-
posit capit expans screen
risk new produt introduct
pop-seq pipelin key area growth multipl
compani expect sizeabl program init statu
uk nh uk biobank us contribut
expect program what ilmn visibl
return dd/teen growth
roll
ramp popul health initi nh uk biobank us
short interest float
see compar aubagio teriflunomid
view fit treatment paradigm
multipl sclerosi ms key differenti featur
view commerci potenti world
current ip posit strategi
gener teriflunomid avail
avial extend exclus
view opportun indic
mechan translat differenti
beyond ms give confid mechan
profil ai diseas rel inhibitor
action translat diseas
initi phase data
initi phase sad/mad studi
phase data rrm
biolog mechan
mechan uniqu suit develop ibd
short interest float
key lesson mirvetuximab soravtansin develop
ovarian cancer strategi futur anti-
follow forward-i disappoint
soraya studi benchmark
develop posit
reason confid fr high patient captur
next-gen fr differenti
reason confid studi posit
mirvetuximab develop strategi timelin
develop regulatori strategi mirvetuximab
combin set also platinum sensit agnost set
program
initi pivot soraya studi mirvetuximab soravtansin fr-high
ovarian cancer
initi forward-ii data platinum-agnost ovarian cancer patient mid-
possibl
updat triplet combin avastin carboplatin data fall
updat monotherapi combin data venetoclax and/or
azacitidin american societi hematolog
preclin data next gener fr-target american
associ cancer research
ind file partner op
short interest float
inhibit fcrn biolog uniqu gear toward treat
see posit mg treatment
differenti vs fcrn inhibitor
recent approv tepezza thyroid eye diseas
develop pathway look like three lead
rational target myasthenia gravi mg
see differenti mg vs fcrn
target indic
ted influenc develop strategi
advantag compar late
stage therapeut clinic develop warm autoimmun
think timelin strategi expand
igg-medi diseas
initi data phase
top-line data phase ascend-mg
initi phase studi mg
interim data phase ascend-waiha trial
top-line data phase
short interest float
unmet need hidraden suppurativa hs especi
approval valid way
humira approv
base ole data futur plan hs
data led initi shine
next trial anoth registrion studi
see shine led unusu high
investor think lack correl
limit hidraden suppurativa clinic
respons score hiscr over- under-emphas
differ symptom hs
level diseas sever hurley stage paper
co-author
statu follow-on indic anca-associ
find open label extens ole shine
program on-going
phase data anca-associ vascul
phase data pyoderma gangrenosum
short interest float
evp bd product strategi daniel spangler head ir
current statu ph tellomak studi lacutamab
leukemia mds/aml learn monalizumab nk cell
countri countri given regulatori feedback intern
progress much delay expect
transit commerci stage compani lumox
azn begin ph trial monalizumab
proceedingani win roadblock thu far
squamou cell carcinoma head neck scchn await
data cohort io pretreat io nave monalizumab
cetuximab scchn rational combin
point excit combin monalizumab
monoclon antibodi
saw promis result macrophag checkpoint anti-
azacitadin myelodysplast syndrom acut myeloid
late-preclin program enter clinic
nk engag platform differenti competitor
patricular indic patient expect differenti
manifest clinic benefit
azn recent stop develop antagonist anti-
egfrm non-small-cel lung cancer nsclc continu
castrate-resist prostat cancer chang
enthusiasm approach program
approv lumox eu
data cohort io pretreat patient ph trial monalizumab
cetuximab r/m scchn
data cohort io naiv patient ph trial monalizumab
cetuximab r/m scchn
lift partial clinic hold ph tellomak trial lacutamab
data expans cohort ph trial imfinzi non-
small cell lung cancer hepatocellular carcinoma
short interest float
analyst daniel antalffi medic suppli devic
sale came expect across board ex
weak across busi underli market
rental primari driver miss
fundament still intact sign give confid
reiter guidanc month earli novemb
noth chang peak penetr perspect
chang last month quarter
process product develop regulatori
statu inogen one suppli constraint
process need undertak integr new aera
announc januari much domest miss
system think margin impact new
attribut suppli constraint vs lower hme
aera acq go-to-market strategi first launch
approach guid chang vs
ensur consist quarter
posit quarterli report posit quarterli report could prove posit
stock includ posit commentari surround manufactur
pipelin product launch advanc poc non-invasive ventil
featur
short interest float
thought recent quarter surpris
expect consolid take place healthcar
data analyt space market still earli inning
build guidanc drive deceler
talk data set differenti
offer ehr vendor
lever acceler growth put
walk us data lake strategi data
take higher invest spend margin impact etc
lake solut differenti offer player
opportun remain adjac market think
outsid healthcar
end market payer provid pharma/lif scienc
think target leverag debt
focus energi
repric use cash
short interest float
blain davi head ir
see willow studi
main driver contribut sale
given heterogen diseas see better respons
could lever play near futur
among sub-group
quarter worth strong sale plan chang
plan enrich studi
sale strategi way move forward
stratif measur could implement
need done execut strong launch eu
trial design could expect
launch go arikayc
statu arikayc studi front-lin set
arikayc submit file japan refractori non-tubercul mycobacteria
short interest float
reimburs friction eas think prior
direct insurers/provid pa submiss acceler
total pa submiss submit insp hub vs outsid
expect decis remain commerci hold out
reason assum any/al
insur pick coverag expect effect
provid similar impact saw aetna effect
term increment procedur timelin
still expect reimburs decis japan earli
insp commerci strategi
think potenti revenue contribut
expect dtc effort continu past pilot region
region recent ad impact campaign
measur expect hear metric new
account open and/or procedur pick trend go forward
management confid build sale infrastructur support
account right level think balanc
growth new vs exist account
realist see offici coverag region mac
point management think procedur econom could potenti
commerci reimburs and/or still yet write
medicar reimburs final local coverag decis lcd earli
japan reimburs expect earli could allow
commerci reimburs least par us/ europ
pediatr w/ syndrom label indic like discuss
fda like know earn call
effect pace/veloc adopt stand
short interest float
analyst daniel antalffi medic suppli devic
overal insulin pump market grow
rais sale guidanc vs
chang drive seem fairli meaning growth
start year been/hav biggest sourc
acceler last month barrier adopt
fell drive penetr higher barrier remain
type penetr today expect
look ahead approach guidanc chang
given signific out-performance ytd beyond
tougher y/i compar think sale guidanc
see success insulin-depend type
put take caus believ adopt
recent quarter drive particularli given
momentum might slow either europ
happen without specif
product sustain barrier
adopt exist type patient vs type type
penetr today peak penetr patient
product launch horizon integr pump/cgm expect launch
addit phone control
fda approval/product launch expect fda approv launch
product launch fda approv octob omnipod/humulin
expect launch market time frame
latest statu horizon could data releas
ada give manag confid
timelin featur differenti horizon competitv
pump system market address issu
barrier adopt today
short interest float
analyst richard newitt medic suppli devic
management revamp resource/rep alloc initi back
propel busi start impact
reason year sustain growth trajectori propel
investor think compon growth
base biz sinuva
establish offici j-code effect oct
impact sinuva util expect j-code
signific impact specif
didnt establish refer price dec sinuva
outlook secur one next cycl
management view likelihood potenti outcom potenti
decis blend asp substanti price vs comment vs
refer set level sinuva current asp establish
management sens if/when privat payor adopt
impact establish specialti pharmaci
sp partner orsini streamlin physician support hub
sinuva uptak expect addit partnership
announc extent sp help decreas relianc buy-
next step toward dcb pma submiss follow
ascend trial miss primari endpoint earli oct
level investor expect gm take step back
due invest management anticip return
establish refer price earliest potenti time late feb/march
dcb pma submiss requir fda determin step need
taken
bio-absor long-act implant earli launch
anticip
short interest float
commerci strategi caplyta launch success highli generic schizophrenia market
could remind us lumateperon mechan action uniqu among antipsychot
upcom bipolar depress studi readout bar readout clinic meaning
could remind us regulatori approv strategi lumateperon bipolar depress launch second bipolar
frame commerci opportunti bipolar depress label expans would need chang commer footprint
market spend potenti new opportun
updat pursuit major depress disord mdd indic
provid updat pipelin prioriti new product vs addit indic lumateperon
caplyta us launch schizophrenia late
initi anoth phase monotherapi studi bipolar depress
phase bipolar depress readout lumateperon
initi phase studi parkinson
initi phase studi lumateperon mdd
short interest float
angelo head ir
analyst puneet souda life scienc tool diagnost
guid guid came consensu safe
recent acquisit impact singular jungla
expect test guid conserv follow miss
perform acquisit expect drive
higher revenue guid asp expans come
growth long term expect meaning margin
expans singular
menu expans nip progress
burn expect see
grow pre-nat screen offer key menu
expans initi
new area busi follow invest intern
asp pressur blend asp declin
market direct channel detect program serv rare
investor expect see rebound
diseas biopharma what next
announc new biopharma academ partnership
sale rep expans product ramp
continu invest volum growth
import area focu
short interest float
prepar commerci til program
commerci challeng seen car-t applic
til work mitig challeng investor
assum limit center current use aldesleukin
io therapi approv melanoma mid-term
 tlr agonist oncolyt virus next-gen vaccin
ensur lifileucel remain competit
barrier entri develop til therapi
uniqu iova approach collect select
uniqu challeng til move
tumor type address challeng
expect data nsclc scchn cll
identifi good biomark differenti
mani women die cervic cancer commun
respond non-respond lifileucel
poor access health care support access
current per patient cost-of-good lifileucel
low could figur get process improv scale
plan global registr commerci
recent licens next-gen nv
asset differ aldesleukin next gener
program develop expect greatest benefit
combin til new vs aldesleukin
data pivot studi lifileucel melanoma
submit bla lifileucel melanoma
data pivot studi cervic cancer
short interest float
talk competit landscap brand ibs-c therapi
talk givlaari givorisan opportun partner
us expect price
alnylam think launch
volum dynam year
product econom ironwood
market opportun refractori gerd
provid us updat ex-u linaclotid
talk phase trial design
much read-through term abdomin pain reduct
ibs-d get phase result ibs-c
phase data abdomin pain associ ibs-d
phase data refractori gerd
short interest float
see approv sulopenem ciai given
could remind us design cuti uuti trial
phase narrowli miss primari endpoint
subgroup analysi
compani didnt increas sampl size ciai studi
view peak market potenti sulopenem
interim yet miss final analysi suggest first
three indic approv
second portion trial probabl differ result
true may caus differ
recent secur debt financ see cash
runway compani
could factor potenti make second portion cuti
uuti trial behav differ first portion
phase data sulopenem complic uncompl uti
potenti nda submiss sulopenem
potenti submiss sulopenem
short interest float
analyst daniel antalffi medic suppli devic
view current statu jnj devic busi within
think portfolio holist whether
competitv landscap strategi evolv
devic busi time
right piec place lead competitor
driver think within medic devic
long under-sc cardiolog
specif keep path acceler sale
growth sustain market growth busi
drive recoveri below-market
biggest risk mind reaching/achiev in-lin
market growth year ever
what strategi continu drive oper leverag
market price seem perpetu pressur
compani lose compet foot believ
top player medic devic long-term without scale
discuss exactli digit surgeri mean
look like digit surgeri procedur look differ
mi procedur done today exactli expect
may analyst day
analyst day schedul host medic devic busi review day
expect approv compani hope gain approv darzalex
subcutan formul
short interest float
market oppti acut prophylaxi
expect support data candid
differenti current standard care
recept market oral prophylaxi given effect agent
prior acut trial similar/differ
valid plasma kallikrein target
trial design endpoint
strategi place minim subject standard
care use trial
see berotralstat affect develop timelin
see studi refractori diabet
phase acut hereditari angioedema data
phase studi initi prophylaxi
short interest float
talk initi launch xpovio real
talk reason confid ahead top-lin
world toler profil play vs clinic trial experi
boston trial readout earlier line multipl myeloma
averag time therapi
larg initi storm set multipl myeloma
larg boston opportun
talk overal develop strategi xpovio
think busi develop
dlbcl beyond
commerci strategi europ
talk current cash posit runway
top-lin data phase boston studi relapsed/refractori multipl
myeloma rrmm prior therapi earli nda submiss
ema regulatori decis xpovio penta-refractori multipl myeloma
submiss xpovio diffus larg b-cell lymphoma dlbcl
top-lin phase seal data xpovio de-differenti liposarcoma
regulatori decis fda selinexor dlbcl mid-lat
initi confirmatori phase dlbcl studi selinexor
rituximab-gemcitabine-dexamethasoneplatinumin r-gdp
initi sever new clinic trial selinexor combin across
hematolog malign solid tumor dlbcl nsclc etc
short interest float
larg market opportun tipifarnib hra
erk inhibitor erk inhibitor
mutant indic pathway indic
disappoint past make differenti
much hurdl clinic execut genet screen
menin-ml inhibitor talk rational
scchn standard practic today
target menin-ml aml believ differenti
potenti next develop step expand scchn
opportun earlier line combin treatment
addit data on-going phase ii trial tipifarnib cmml
complet dose-escal select phase trial
erk inhibitor enrich scc
achiev phase dose-escal trial menin-ml
inhibitor potenti enrich aml mll-rearrang
genet defin subgroup year
initi registration-direct trial tipifarnib aitl
initi proof-of-concept studi tipifarnib pancreat cancer
registr aim-hn studi enrol complet
short interest float
long-term vision compani area
key task progen portfolio next
identifi key acceler revenu growth
month lantheu need accomplish
growth opportun defin alreadi
pipelin opportun excit
market share contrast imag agent use
could discuss rational recent announc
acquisit progen
see path ebitda ep accret
potenti nda submiss pyl prostat cancer
short interest float
moder daniel antalffi medic suppli devic
fairli acquist recent specif
current posit sale forc
past month across board integr
think structur go forward given recent
progress far target term cost
sale synergi activ posit compani
look compani exposur asia-pacif specif
china seen impact far due coronaviru
recent acquir biolog patch busi admedu
effect management think oper
intiti payment well addit potenti
earnout payment base mileston discuss
mileston strategi place
reach mileston
increment addit expect cardiocel
vascucel potenti market target
impact exisitng product line xenosur
compani recent issu guidanc key
driver achiev growth midpoint
potenti sourc either upsid downsid surpris
guidanc
compani mention cost effect european mdd
mdr transit visibl
issu resolv factor guidanc
acquir product contribut meaning revenu contribut
continu ramp adopt cardiocel recent acquisit
continu activ compani fairli acquisit
last year expect see continu activ compani
rep addit compani launch offic singapor
continu develop salesforc presenc new rep
short interest float
margetuximab talk clinic regulatori
think initi data modul
statu program metastat breast cancer mbc
mahogani studi
fda requir approv
flotetuzumab think next
commerci opportun margetuximab mbc
develop step competit landscap
busi develop strategi margetuximab
help set expect ahead phase pd-
breast cancer partnership discuss progress
bispecif updat
strategi margetuximab gastric cancer
margetuximab oncolog drug advisori committe odac meet expect
follow pdufa date
final os analysi phase sophia studi event
initi safeti efficaci data modul phase ii/iii mahogani studi
margetuximab gastric cancer
defin potenti registr path flotetuzumab patient primari
induct failur earli relaps aml pend discuss fda
initi data flotetuzumab combin studi
phase clinic updat bispecif scientif
confer select indic develop
short interest float
presid
regard dose regimen resmetirom
think patient popul test
discuss learn phase implement
phase trial design
assum abl effect clear liver fat wont
get progress fibrosi time-fram expect
see full impact fibrosi
maestro-nash success much competit overlap
expect may target patient vs oca
think combin market
point could resmetirom use combin someth like
maestro-nash impact efficacy/treat effect
expect given patient popualt differ rel
discuss rational behind run parallel phase
studi maestro-nash maestro-nafld
rational use slightli differ definit nash
resolut sever competitor
els could resmetirom util outsid nash
hyperlipidemia current develop plan
indic outsid nash
potenti competit readthrough vktx top-line result phase
studi nash patient
initi data open label patient portion phase
pivot data expect phase maestro-nash trial resmetirom
nash patient
short interest float
see strategi afrezza diabet evolv
launch afrezza proceed brazil
next month signific remain
calibr expect braziian market
obstacl afrezza prescript growth
regulatori pathway current timelin look like
seen advertis new sale rep meant
foreign partnership afrezza
fill open vacanc expans current sale
forc target sale rep toward high opportun
streamlin commerci messag around
afrezza past year found reson
prescrib
on-going trial tret
proceed pah expect around time
see posit tret within pah portfolio
partnership shape
view bring forward new pipelin asset opportun
see greatest upsid potenti
fda updat pediatr studi afrezza
init phase trial afrezza india region partner cipla
initi phase portion pediatr studi afrezza
file registr afrezza australia region partner amsl diabet
updat partner pulmonari arteri hypertens
pah program bridg switch studi tret
short interest float
market potenti ganaxolon epilepsi
upcom readout epilepsi kind
potenti biomark factor
efficaci would clinic meaning phase studi
talk market opportun ganaxolon
anyth new regard thought clinic path
depress mdd/ppd franchis paus right
would clinic meaning readout phase
provid updat think ou
ganaxolon new opportun tuber sclerosi
explain capit need beyond
end phase meet fda ganaxolon rse
start phase trial ganaxolon
start phase rse studi ganaxolon
phase marigold studi readout ganaxolon epilepsi
short interest float
therapi group mitg ryan weispfen vice-president head ir francesca
analyst daniel antalffi medic suppli devic
mitg perform past quarter produc flat result
much share surgic busi lose robot
larg driven erp system upgrad issu
last year hugo major upcom catalyst
under-perform attribut one-tim upgrad issu
stem share loss hugo launch one
expect share loss continu share stabil due
implement improv visibl issu fulli
innov underli market dynam
resolv would mitg sale growth ex issu
relat hugo robot surgeri view
potenti market opportun competit landscap like
look ahead year acceler mitg
shift one player today three major player year
growth given start hugo roll-out despit feel like
time like market expans stori vs share
above-market growth even
grab drive manag confid
 pivot data june us pivot trial present minim
expect ada american diabet associ scientif session
 launch expect launch minim advanc hybrid close
loop system new cgm contin glucos monitor type
 launch expect spring approv launch percept deep brain
stimul interstim micro interstim surescan mri lead submit
await us fda approv launch spring
short interest float
investor express concern increas role
import keytruda would impact neo-
keytruda top-line asset pipelin
adjuv /- adjuv effect adjuv alon
could diversifi mrk revenu base
excit anti-tigit build year talk
major uncertainti keytruda futur happen
program take market-leadership
loss exclus think keytruda
franchis long-term approach take extend
franchis life-cycle portion keytruda sale expect
lost biosimilar competit five year post loe
major sourc new keytruda revenu go forward may come
early-stag indic indic project
data ph studi vericiguat heart failur
present next month view blockbust product
might avoid hurdl adopt entresto face
said street underappreci top-line ep
potenti program think street get wrong
march ph vital studi vericiguat acut heart failur
ph trial keytruda lenvima renal cell carcinoma
ph trial opdvio cabometyx rcc
ph trial keytruda bladder cancer
june approv keytruda cutan squamou cell carcinoma
short interest float
moder richard newitt medic suppli devic
key tailwinds/headwind consid revenue
compani minim potenti neg impact top line
implement cost restructur margin improv initi
seen qtr premier gpo contract
prefer provid distributor agreement think
increment contribut item beyond
china compris signific revenu growth
contribut level impact management expect see
coronaviru
realist think compani eventu sustain
hsd revenue grower futur expect slower revenue
growth ensur consist margin/cash flow improv
biggest opportun drive margin improv
close gap vs peer group averag main margin
improv driver expect see tangibl
indic improv within
think cianna revenu contribut go
forward expect see cianna revenu growth acceler
given recent ce mark scout surgic guidanc
recent resolv arcadia launch progress
expect product contribut revenue meaning
revenu cadenc appropri product
timelin expect around wrapsodi studi
still expect launch
short interest float
make mrsn platform differenti
talk lesson learn roch disappoint
compani space
reason discontinu former lead program
effort lifastuzumab vedotin reason confid
mrsn approach could succeed especi regard durabl
implic platform
talk rational move ahead second
speak advantag disadvantag
updat dose escal data dolaflexin phase
trial societi gynecolog oncolog sgo abstract
present interim data expans cohort platinum-resist
ovarian cancer nsclc
present matur expans cohort data
initi phase trial dolasynthen
disclos develop candid support data target
final platform design target evalu select first sting agonist
develop candid
short interest float
prader-willi syndrom pw unmet
could expect potenti registr
portion studi
livoletid amelior hyperphagia
livoletid differ emerg pw therapi
see studi
goal nevanimib congenit adren hyperplasia
popul look
investor cautiou subset subset
see nevanimib
analysi give confid replicate/show
statu studi nevanimib issu
better efficaci
encount amend protocol
livoletid phase zephyr data prader-willi syndrom
nevanimib phase cohort top-lin data congenit adren hyperplasia
short interest float
view potenti competit kra field
regulatori expect efficaci
could differenti other far behind
versu
priorit combin strategi
regulatori efficaci bar potenti acceler
approv monotherapi nsclc
expect updat solid tumor
much durabl data anticip
provid high level ration target mutat
asset
also discuss sitravatinib pivot clinic develop
identifi clinic candid target krag mutat
fda meet discuss acceler approv pathway nsclc
initi combin trial cetuximab kra
initi phase trial kra tumor
initi combin trial afatinib kra
nsclc
updat clinic data solid tumor
short interest float
think pricing/revenu opportun maralixibat
provid detail dataset submit
alagil syndrom alg potenti growth opportun
fda conjunct nda maralixibat includ non-
indic
clinic vitro studi mous carcinogen studi food
regard potenti fda approv maralixibat fda
provid feedback optim dose alg
progress volixibat data shown date
anticip potenti label maralixibat alg cover
path move forward
patient subset
european strategi maralixibat focus
maralixibat time still expect nda submiss
expect launch updat
updat regard timelin ema discuss
enrol top line data readout march-pfic phase
enrol complet march-pfic
maralixibat top-line data pfic
short interest float
could talk darpin platform potenti
assembl pipelin oncolog asset
thought behind strategi long term goal
could discuss thought market opportun
opportun pipelin excit
abicipar compar standard care new product
approv well late stage asset
thought inflamm risk abicipar
adopt real-world practic
could discuss collabor mp
go co-develop
capit need
approv launch abicipar namd us eu
initi abicipar phase studi dme patient
phase data pi-combo trial
initi combin trial
short interest float
tafasitamab launch prepar us
updat frontlin dlbcl trial tafa
accomplish complet next month
expect top-lin readout
comment deal establish
increas physician awar tafa novel
infrastructur ou market expand
therapi dlbcl
collabor plan budget
execut tafa trial outsid dlbcl latest updat
talk tafasitamab competit posit nhl
compar novel therapi car-t bispecif
eu regulatori submiss tafasitamab
us approv tafasitamab r/r dlbcl
short interest float
upcom readout spirit endometriosi
stock work well last year hero readout
investor interpret benchmark primari
think market under-appreci women health opportun
prostat cancer opportun simpli much larger
think long-term market potenti revenu
expect market posit relugolix
ramp relugolix overal gnrh antagonist class
prostat cancer particular patient group think
abbvi recent guidanc
relugolix serv better
main differ endometriosi
push pull regard likelihood
uterin fibroid market think go-to-market
secondari endpoint castration-resistance-fre surviv hero
hit
submiss relugolix uterin fibroid
april nda submiss relugolix uterin fibroid
phase data relugolix endometriosi spirit
phase data relugolix endometriosi spirit
nda submisss relugolix prostat cancer
phase data relugolix prostat cancer castration-resistance-fre
short interest float
analyst puneet souda life scienc tool diagnost
code chang cash collect trend
counsyl revenu outlook non-invas prenat test
core hereditari busi improv
nipt product would describ volum growth
revenu accrual denial rate impact volum
price opportun
genesight earli experi
ceo search still earli thing progress
unitedhealthcar impact volum uptak
ceo search what timelin
earli progress handl pre-author
genesight sale forc expand sale forc
price pressur could discuss dynam lab benefit
increas primari care physician pcp call point
manag lbm price pressur compani
impact margin next two year
subsid
lead margin expans
genesight reimburs decis commerci payer
short interest float
repres fred colen presid ceo christoph clark
analyst daniel antalffi medic suppli devic
recent direct offer cash hand
tiara ii mani site enrol rate
exit long cash posit fund daili
long take enrol patient ce mark trial
oper compani conduct sever trial
ce mark still possibl
current burn rate quarterli perspect
reduc conserv cash financ option
chang reduc last two year shift
manag strategi refocu effort potenti
partner retain asset
tf/t product design complet soon might enter
clinic trial might trial design tiara tf/t
manag frame mitral market opportun
mani potenti competitor come market
support competitor tiara differenti
reduc next regulatori mileston
transcathet mitral valv develop
give manag confid clinic data submit
suffici secur fda approv
ce mark studi tiara-ii studi on-going expect ce mark approv
trial intiat compani alreadi discuss fda potenti tiara pivot
trial design management could file initi pivot trial
short interest float
promis signal
beyond chemotherapi therapeut
data present last year
dose expans nsclc ovarian tnbc
scchn enrich patient
select four tumor
orthogon relationship
express share nsclc extend tumor type
tnbc tumor predict
benefit still exclud high patient set
combin preclin support might move
clinic
approach thu far priorit combin
includ confid anti-
would synergist benefit patient
help us understand biolog target second
find-io find new target discuss lilli
express correl immun phenotyp
back find-io collabor
dose expans data nsclc
ovarian tnbc scchn biopsi requir retrospect analysi siglec-
ind decoy
short interest float
simpson head north america ir cori twine ir offic
mani larg pharma start pivot refocus
current commerci patient adakveo
oncolog novarti differenti competit
percentag medicaid vs medicar group patient
sinc public monaleesa overal surviv data
higher barrier reimburs
seen inflect kisqali prescript volum sale
current manufactur capac kymriah
foundat medicin companion diagnost piqray
approv decemb impact approv
much increment capac provid improv
much increas test rate anticip
capmatinib recent receiv prioriti review februari
on-going effort prepar commerci
ofatumumab bla approv ms us
cosentyx bla approv nr-axspa us
entresto phase data readout post-acut mi
capmatinib nda approv nsclc us
inclisiran nda approv hyperlipidemia us
xolair bla approv nasal polyp us
short interest float
assumpt inform novo guidanc
prioriti diabet pipelin asset novo commit
initi metric rybelsu launch level
diabet long term
access/reimburs achiev us ex-
lesson novo learn liraglutid obes
segment previous share
develop launch inform
share win deriv new oral option
victoza demonstr potenti alzheim
might novo diabet sale split evolv next year
novo plan investig opportun
insulin non-insulin product
hemlibra uptak continu impact novo hemophilia
insulin price trend inform
next year rel past year
sale novo hemophilia pipelin off-set share loss
semaglutid phase result obes
semaglutid phase ii result nash
amylin phase ii result obes
la-gdf growth differenti factor phase ii result obes
concizumab anti-tfpi phase result hemophilia
short interest float
past two year youv undergon transform
compet often go head head
busi strategi left
walk us solut suit includ enterpris
think growth arc
healthcar evolv legaci transcript
softwar integr clinician workflow
keep night healthcar businessexecut
ehr friend foe
regulatori
could walk new solut radiolog code
use cash follow auto spin
product sold transit saa impact
financi near term
short interest float
regard stock reaction primros top-lin data last
compani learn interim analys done
year think investor miss
far prolong trial could data
increment inform anticip
disclosur prior final readout
